Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Renal physiology

TRPC5 inhibition to treat progressive kidney disease

Focal segmental glomerulosclerosis (FSGS) is a common and progressive form of kidney injury for which treatment options are limited. New findings from a study in animal models of FSGS suggest that a small molecule inhibitor of the TRPC5 ion channel could provide therapeutic benefit.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Brown, E. J., Pollak, M. R. & Barua, M. Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney Int. 85, 1030–1038 (2014).

    Article  CAS  Google Scholar 

  2. Reiser, J. et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat. Genet. 37, 739–744 (2005).

    Article  CAS  Google Scholar 

  3. Winn, M. P. et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308, 1801–1804 (2005).

    Article  CAS  Google Scholar 

  4. Schaldecker, T. et al. Inhibition of the TRPC5 ion channel protects the kidney filter. J. Clin. Invest. 123, 5298–5309 (2013).

    Article  CAS  Google Scholar 

  5. Zhou, Y. et al. A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models. Science 358, 1332–1336 (2017).

    Article  CAS  Google Scholar 

  6. Tian, D. et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci. Signal. 3, ra77 (2010).

    Article  Google Scholar 

  7. Wang, X. et al. TRPC5 does not cause or aggravate glomerular disease. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.2017060682 (2017).

  8. Ilatovskaya, D. V. et al. Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels. Sci. Rep. 5, 17637 (2015).

    Article  CAS  Google Scholar 

  9. Ilatovskaya, D. V. & Staruschenko, A. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases. Am. J. Physiol. Renal Physiol. 309, F393–F397 (2015).

    Article  CAS  Google Scholar 

  10. Bröker-Lai, J. et al. Heteromeric channels formed by TRPC1, TRPC4 and TRPC5 define hippocampal synaptic transmission and working memory. EMBO J. 36, 2770–2789 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

J.v.d.W. is supported by the European Union's Horizon 2020 Marie Skłodowska-Curie actions (grant agreement no. 748058).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jenny van der Wijst or René J. M. Bindels.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

van der Wijst, J., Bindels, R. TRPC5 inhibition to treat progressive kidney disease. Nat Rev Nephrol 14, 145–146 (2018). https://doi.org/10.1038/nrneph.2018.4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2018.4

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing